MedTrace Logo

D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia

NCT01102803 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-02-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the utility of post-session administration of D-cycloserine to enhance fear extinction in a sample of people with acrophobia who will be treated with CBT.

Conditions

  • Phobic Disorders

Interventions

BEHAVIORAL

Individual Cognitive Behavioral Therapy (CBT)

The aim of CBT is to help participants become more comfortable with heights situations. Participants will receive 2 sessions over two weeks of individual CBT.

DRUG

D-Cycloserine

D-Cycloserine

DRUG

Placebo

Sugar Pill

Sponsors & Collaborators

  • Southern Methodist University

    lead OTHER

Principal Investigators

  • Jasper Smits, Ph.D. · Southern Methodist University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01102803 on ClinicalTrials.gov